Emergent Health Corp (EMGE) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEmergent Health Corp (EMGE) trades at $0.0001. Emergent Health Corp. focuses on developing and selling regenerative medicine, nutraceuticals, and phytonutritionals. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for EMGE: EMGE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EMGE against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 24 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
EMGE: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Emergent Health Corp (EMGE) Healthcare & Pipeline Overview
Emergent Health Corp., based in King of Prussia, PA, develops and sells regenerative medicine, nutraceuticals, and phytonutritionals, including Vita-Stim, Neuvitale, Hungarest, and EmergentO2. The company distributes its products through health food stores, pharmacies, and other retail outlets in the U.S. and internationally, targeting health-conscious consumers.
What Is the Investment Thesis for EMGE?
Emergent Health Corp. operates in the regenerative medicine and nutraceuticals market, which is characterized by increasing consumer interest in health and wellness. Key value drivers include the company's ability to innovate and introduce new products, expand its distribution network, and effectively market its products to health-conscious consumers. However, the company's negative profit margin of -241.5% and ROE of -164.2% raise concerns about its financial sustainability. Growth catalysts include potential partnerships with larger retailers and expansion into new international markets. The company's high beta of -6.98 suggests high volatility relative to the market. Investors should carefully consider the company's financial performance and market position before making investment decisions.
Based on FMP financials and quantitative analysis
EMGE Key Highlights
Market Cap of $0.00B indicates a small-cap company with limited resources.
- Profit Margin of -241.5% signals significant losses and potential financial instability.
- Gross Margin of 66.5% suggests strong pricing power and efficient production, but is offset by high operating expenses.
- ROE of -164.2% indicates poor return on equity, reflecting inefficient use of shareholder investments.
- Beta of -6.98 suggests the stock moves inversely and more dramatically than the market, indicating high volatility.
Who Are EMGE's Competitors?
EMGE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
| GRUSF Grown Rogue International Inc. | $0.44 | -2.16% | $110M | 439-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are EMGE's Key Strengths?
Proprietary formulations of regenerative medicine and nutraceutical products.
- Established distribution network through health food stores and pharmacies.
- Focus on innovative products and personalized nutrition solutions.
- Brand recognition and customer loyalty in the niche market.
What Are EMGE's Weaknesses?
Negative profit margin and ROE indicate financial instability.
- Limited market capitalization restricts resources for growth.
- High beta suggests significant stock volatility.
- Dependence on a niche market may limit scalability.
What Could Drive EMGE Stock Higher?
Potential partnerships with major retailers to expand product distribution (Timeline: 6-12 months).
- Launch of new regenerative medicine products (Timeline: 12-18 months).
- Increasing consumer demand for nutraceuticals and alternative health solutions.
- Expansion into new international markets with growing healthcare spending.
- Implementation of enhanced marketing and branding strategies.
What Are the Key Risks for EMGE?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger pharmaceutical and nutraceutical companies.
- Strict regulatory oversight and potential changes in regulations.
- Pricing pressures and the need to maintain competitive pricing.
- Product recalls or safety concerns impacting brand reputation.
- Negative profit margin and ROE indicate financial instability.
What Are the Growth Opportunities for EMGE?
- Expansion into New International Markets: Emergent Health Corp. has the opportunity to expand its distribution network into new international markets, particularly in Asia and Europe, where there is growing demand for nutraceuticals and regenerative medicine. This expansion could significantly increase the company's revenue and market share.
- Development of New Products: Investing in research and development to create new and innovative products in the regenerative medicine and nutraceuticals space. This could attract new customers and increase sales. Focus on emerging trends like personalized nutrition and plant-based supplements could provide a competitive edge. The timeline for new product development is estimated at 12-18 months.
- Strategic Partnerships with Retailers: Forming strategic partnerships with major retailers and pharmacy chains to increase product visibility and accessibility. This could involve placing products in prominent locations within stores and offering exclusive promotions. Collaborations with online retailers could also expand the company's reach. Negotiations and implementation are expected to take 6-12 months.
- Enhanced Marketing and Branding: Implementing a comprehensive marketing strategy to build brand awareness and educate consumers about the benefits of the company's products. This could involve online advertising, social media campaigns, and collaborations with health and wellness influencers. A strong brand presence can differentiate Emergent Health Corp. from competitors. The marketing plan can be rolled out within 3-6 months.
- Focus on Personalized Nutrition: Tailoring products and services to meet the individual needs of customers through personalized nutrition programs. This could involve offering customized supplement plans based on genetic testing and lifestyle assessments. Personalized nutrition is a growing trend in the healthcare industry, and Emergent Health Corp. can capitalize on this by offering innovative solutions. Implementation of personalized programs could begin within 9-12 months.
What Are EMGE's Competitive Advantages?
- Proprietary formulations of regenerative medicine and nutraceutical products.
- Established distribution network through health food stores and pharmacies.
- Brand recognition and customer loyalty in the niche market.
- Focus on innovative products and personalized nutrition solutions.
What Does EMGE Do?
Emergent Health Corp., established in 2006 and based in King of Prussia, Pennsylvania, operates within the healthcare sector, focusing on the development and sale of regenerative medicine, nutraceuticals, and phytonutritionals. The company's product line includes Vita-Stim, a nutrient designed to enhance the immune system, nourish stem cells, and maintain overall health. Neuvitale, another key product, also nourishes stem cells and acts as a methyl donor to protect DNA. Hungarest is marketed as a diet aid that controls appetite by targeting the brain and stomach, while EmergentO2 is a water oxygenator intended to increase oxygen levels in the bloodstream. Additionally, the company offers products aimed at reducing facial wrinkles. Emergent Health Corp. distributes its products through a network of health food stores, pharmacies, and various other retail outlets, both within the United States and internationally. As of August 26, 2014, Emergent Health Corp was taken private, marking a significant transition in its corporate structure.
What Products and Services Does EMGE Offer?
- Develops regenerative medicine products.
- Sells nutraceuticals to enhance health.
- Offers phytonutritionals for dietary benefits.
- Distributes Vita-Stim to boost the immune system.
- Provides Neuvitale to nourish stem cells and protect DNA.
- Markets Hungarest as a diet aid for appetite control.
- Sells EmergentO2 to increase oxygen levels in the blood.
- Offers products to reduce facial wrinkles.
How Does EMGE Make Money?
- Develops and manufactures regenerative medicine, nutraceuticals, and phytonutritionals.
- Sells products through health food stores, pharmacies, and retail outlets.
- Generates revenue through direct sales to consumers and wholesale distribution.
- Focuses on marketing and branding to drive product demand.
What Industry Does EMGE Operate In?
Emergent Health Corp. operates in the competitive drug manufacturers - specialty & generic industry. This sector is characterized by companies that develop, manufacture, and market specialized pharmaceutical products and generic drugs. The market is driven by an aging population, increasing healthcare spending, and growing demand for nutraceuticals and regenerative medicine. Competitors include BXRXQ, CVHIF, CYPS, KLDO, and QMDT. The industry is subject to strict regulatory oversight and faces challenges related to pricing pressures and competition from larger pharmaceutical companies.
Who Are EMGE's Key Customers?
- Health-conscious individuals seeking to improve their overall well-being.
- Consumers looking for natural and alternative health solutions.
- Individuals interested in regenerative medicine and anti-aging products.
- Customers purchasing through health food stores, pharmacies, and online retailers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 711 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 60 |
| 2026-08-26 | 60 |
| 2026-08-29 | 60 |
| 2026-09-01 | 60 |
| 2026-09-04 | 60 |
| 2026-09-07 | 60 |
| 2026-09-10 | 60 |
What changed?
The score has stayed at 60.
Over the same 18 days the stock moved +0.0%.
Company Profile
Emergent Health Corp operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in King of Prussia, US. The company is led by CEO James W. Zimbler. EMGE has traded publicly since 2009.
EMGE Revenue & Earnings Trend
In Q3 FY2024, EMGE generated $0 in top-line revenue. The company recorded a net loss of $65K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare.
Key Financial Metrics
Return on equity for Emergent Health Corp stands at 90.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Emergent Health Corp's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
EMGE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary formulations of regenerative medicine and nutraceutical products.
- Established distribution network through health food stores and pharmacies.
- Focus on innovative products and personalized nutrition solutions.
- Brand recognition and customer loyalty in the niche market.
Bear Case
- Negative profit margin and ROE indicate financial instability.
- Limited market capitalization restricts resources for growth.
- High beta suggests significant stock volatility.
- Dependence on a niche market may limit scalability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2024 | $0 | -$64,545 | -$0.0002 |
| Q2 FY2024 | -$460,658 | $90,661 | $0.0002 |
| Q1 FY2024 | $460,658 | -$413,784 | -$0.0010 |
Q3 FY2024 · filed 30 Sep 2024 · SEC EDGAR →
Based on FMP financials and quantitative analysis
EMGE Latest News
No recent news available for EMGE.
EMGE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EMGE.
Price Targets
Wall Street price target analysis for EMGE.
EMGE MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EMGE; grades run from A+ (80-100) to F (below 30).
EMGE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Emergent Health Corp. may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and investors should exercise caution due to the increased risks associated with these securities. This tier often includes companies that are distressed, defunct, or unwilling to provide current information to the public, leading to higher information asymmetry.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in EMGE.
- Thin trading volume and wide bid-ask spreads can lead to price volatility.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- The company may not meet the listing requirements of higher exchanges, indicating potential financial or operational issues.
- Lack of regulatory oversight compared to listed exchanges increases investment risk.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile for any warnings or disclosures.
- Consult with a financial advisor before investing in OTC securities.
- Check for any legal or regulatory actions against the company or its officers.
- Understand the risks associated with investing in the OTC Other tier.
- The company has been in operation since 2006.
- Emergent Health Corp. has a history of developing and selling regenerative medicine and nutraceutical products.
- The company distributes its products through health food stores and pharmacies, suggesting some level of market acceptance.
- The company's headquarters are located in King of Prussia, Pennsylvania, providing a physical presence.
- The company has a range of products, including Vita-Stim, Neuvitale, Hungarest, and EmergentO2.
EMGE Healthcare Stock FAQ
Is EMGE a good stock?
Stock Expert AI does not rate EMGE buy, sell or hold. Emergent Health Corp has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Emergent Health Corp do?
Emergent Health Corp. develops, sells, and distributes regenerative medicine, nutraceuticals, and phytonutritionals. Their product line includes Vita-Stim, designed to enhance the immune system and nourish stem cells; Neuvitale, which also nourishes stem cells and protects DNA; Hungarest, a diet aid; and EmergentO2, a water oxygenator.
What do analysts say about EMGE stock?
As of 2026-03-16, there is no available analyst coverage for Emergent Health Corp. (EMGE). The company's financial metrics, including a negative profit margin of -241.5% and ROE of -164.2%, suggest significant financial challenges.
What are the key factors to evaluate for EMGE?
Evaluate EMGE on fundamentals, analyst consensus, and risk factors. The company's high beta of -6.98 suggests high volatility relative to the market. Not financial advice.
How frequently does EMGE data refresh on this page?
EMGE's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EMGE's recent stock price performance?
Emergent Health Corp (EMGE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary formulations of regenerative medicine and nutraceutical products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EMGE overvalued or undervalued right now?
Emergent Health Corp (EMGE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of EMGE?
Yes, most major brokerages offer fractional shares of Emergent Health Corp (EMGE) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited and less reliable than exchange-listed securities.
- Financial metrics should be interpreted with caution due to the company's OTC status and limited disclosure.